Refractory Sarcoidosis Responding to Infliximab

Scott D. Roberts, David S. Wilkes, Richard A. Burgett, Kenneth S. Knox

Research output: Contribution to journalArticle

111 Scopus citations

Abstract

Despite aggressive treatment with conventional therapy, sarcoidosis may be progressive and debilitating. Tumor necrosis factor (TNF)-α is critical in the genesis and maintenance of granulomatous inflammation. Agents developed to inhibit TNF-α have been approved to treat rheumatoid arthritis and inflammatory bowel disease with unprecedented success. As such, physicians are increasingly using these agents to treat patients with other inflammatory diseases, including sarcoidosis. We report a case of refractory sarcoidosis, involving the lung, eyes, skin, and heart, which flared despite aggressive therapy. Oculocutaneous sarcoid dramatically improved after treatment with the anti-TNF antibody infliximab.

Original languageEnglish (US)
Pages (from-to)2028-2031
Number of pages4
JournalCHEST
Volume124
Issue number5
DOIs
StatePublished - Nov 2003

    Fingerprint

Keywords

  • Cutaneous
  • Infliximab
  • Ocular
  • Sarcoidosis
  • Tumor necrosis factor-α
  • Uveitis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Roberts, S. D., Wilkes, D. S., Burgett, R. A., & Knox, K. S. (2003). Refractory Sarcoidosis Responding to Infliximab. CHEST, 124(5), 2028-2031. https://doi.org/10.1378/chest.124.5.2028